Finsbury, The Glover Park Group and Hering Schuppener to Form One Global Firm
Finsbury, The Glover Park Group (GPG) and Hering Schuppener are joining together to create the preeminent global strategic communications and public affairs consultancy. The new firm, Finsbury Glover Hering, will combine the complementary strengths of three of the world’s most respected advisory firms to counsel chief executives, boards and leaders at public and private companies, leading institutions and nonprofit organizations. The combination formalizes the strategic partnership between the three WPP companies, which was formed by Finsbury and Hering Schuppener in 2016 and which GPG joined in 2017.
At a time when companies and institutions face heightened expectations of purpose and transparency, as well as increased public and stakeholder scrutiny, Finsbury Glover Hering is uniquely equipped to provide integrated, tailored solutions to help organizations navigate the financial, legal, regulatory, societal and stakeholder complexities they must consider in shaping their communications. Clients will benefit from Finsbury Glover Hering’s global network of nearly 700 experts in 18 offices in the world’s major financial, government, business and cultural centers, where the firm builds on strong local foundations forged through decades of experience.
The new firm will lead the industry in:
- Public affairs and issues management, with deep policy expertise, a reputation for results and unmatched networks in the world’s capitals;
- Capital markets communications, having advised on more than 1,500 transactions with a total value of more than $2 trillion over the past decade alone; and
- Corporate, crisis and transformation communications, successfully positioning CEOs and other leaders, steering major public and private companies through high-stakes moments of change and helping launch or re-launch organizations to industry leader status.
Finsbury Glover Hering will launch in early 2021. Finsbury founder Roland Rudd and GPG founder Carter Eskew will co-chair the new firm. Alexander Geiser, Managing Partner at Hering Schuppener, will serve as Chief Executive Officer with the support of seasoned global and regional management teams.
Finsbury Glover Hering will be driven by the highly entrepreneurial spirit that inspired its founder firms and intends to offer equity to recruit, retain and incentivize the best established and emerging talent in communications and public affairs. The management team will be investing in the new firm and will own 49.99% of the company alongside WPP, which will retain a majority interest. Mark Read, the CEO of WPP, will also join the Board of Directors of the newly integrated company.
Mark Read said: “We see in Finsbury Glover Hering a tremendous opportunity to establish a new global powerhouse in the strategic communications industry alongside a very talented and highly respected group of leaders. It also aligns with WPP’s strategy of creating simpler, stronger and more integrated client offers.”
Roland Rudd, co-Chairman and founder of Finsbury, commented: “Each of our firms is best in class and together create a new global standard for strategic advice and communications - we’d like to thank our clients for the trust they have placed in us as individual firms over the last decades.”
“We founded GPG with a highly entrepreneurial spirit, and we’re thrilled that we can now also offer a more sustainable value proposition to future generations,” said co-Chairman Carter Eskew.
CEO Alexander Geiser said: “With one global brand, balance sheet and governance, we are formally implementing what has long been reality for us. One firm, one team.”
The company will be headquartered in New York City, with operations in Abu Dhabi, Beijing, Berlin, Brussels, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, London, Los Angeles, Moscow, Riyadh, Shanghai, Singapore, Tokyo and Washington, D.C.
About Finsbury Glover Hering
Finsbury Glover Hering is a new preeminent global strategic communications advisory firm, headquartered in New York City, with almost 700 multidisciplinary experts across the world’s major financial, government, business and cultural centers. The company was formed through the merger of the leading strategic communications consultancies Finsbury, The Glover Park Group (GPG) and Hering Schuppener. The firm provides combined support in Government Relations & Policy and Advocacy, Corporate Reputation & Leadership Strategies, Crisis & Issues Management, Transaction & Financial Communications as well as Business Transformation, supported by Research and Insights, Digital Strategy, Media Planning and Creative Solutions.
Finsbury Glover Hering serves its global client base from offices in Abu Dhabi, Beijing, Berlin, Brussels, Dubai, Dublin, Düsseldorf, Frankfurt, Hong Kong, London, Los Angeles, Moscow, New York, Riyadh, Shanghai, Singapore, Tokyo and Washington, D.C.
Find more information visit www.fgh.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005391/en/
Contact information
Press
USA
Jason Miner
jason@gpg.com
+1 202 295 0118
UK
Dorothy Burwell
dorothy.burwell@finsbury.com
+44 (20) 7251 3801
Europe
Dirk von Manikowsky
dvonmanikowsky@heringschuppener.com
+49 (211) 430 79 265
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom